Abstracts tagged "B-Cell Targets"

Abstract Number: 0015 • ACR Convergence 2025
CDR111 is a novel CD19 and BCMA dual-targeting T cell engager (TCE) for the treatment of severe and refractory autoimmune diseases
Philipp Richle, Stephanie Jungmichel, Alessio Vantellini, André Fonseca, Anna Howald, Fabian Scheifele, Loredana iuliano, Ariadna Vilarrasa, Romina Doerig, Hannes Merten, Philip Knobel, Daniel Lenherr-Frey, Christian Leisner and Leonardo Borras, CDR-Life, Horgen, Zurich, Switzerland
Background/Purpose: B cells and plasma cells are central to the pathogenesis of many autoimmune diseases. While B cell depletion therapies (BCDTs), such as anti-CD20 monoclonal…
Abstract Number: 2454 • ACR Convergence 2025
Longitudinal Analysis of B cell Remodeling in Systemic Lupus Erythematosus Following iPSC-Derived CAR T-cell Therapy
Jonatan Tuncel¹, Trever Greene², Nicholas Brookhouser², Sandeep Kothapally Hanok¹, Seth Peng¹, Alison O’Conor¹, Parastoo Fazeli³, Jennifer Medlin⁴, Cara Bickers², Kelsea Hubka¹, Allison Aguilar¹, Wei Zhao¹, Kyla Omilusik¹, John Goulding¹, Tom Lee², Jode Goodridge², Marie Hu⁵, Veronika Bachanova⁵, Jeffrey Miller⁶, Matthew Lunning⁷, Rebecca Elstrom², Debra Zack¹, Vaneet Sandhu², Bahram Valamehr⁸ and Lilly Wong⁸, ¹Fate Therapeutics, San Diego, ²Fate Therapeutics, Inc., San Diego, ³UMN, ST PAUL, MN, ⁴University of Nebraska Medical Center, Omaha, NE, ⁵University of Minnesota, Minneapolis, ⁶University of Minnesota, Minneaspolis, MN, ⁷University of Nebraska Medical Center, Omaha, ⁸Fate Therapeutics, Inc., San Diego, CA
Background/Purpose: Autologous chimeric antigen receptor (CAR) T-cell therapy is an exciting new potential therapy for autoimmune diseases but limited in scope of application by logistical…
Abstract Number: 1761 • ACR Convergence 2025
The Application of SLE Patient-derived PBMC-induced Mouse Model in Preclinical Pharmacological Studies
Juan Liang¹, Yinlian Zhang², Feng Li², Yingfeng Huang³, Ruixia Zhang³ and Ruixue Dai³, ¹Gempharmatech, Nanjing, Jiangsu, China, ²GemPharmatech, Nanjing, China (People's Republic), ³CytoCares, Shanghai, China (People's Republic)
Background/Purpose: Systemic lupus erythematosus (SLE) is a multisystem autoimmune disorder characterized by the production of autoantibodies targeting nuclear antigens, immune complex deposition, and chronic inflammation…
Abstract Number: 1109 • ACR Convergence 2025
Characteristics of SARS-CoV-2 infected Patients with Rheumatic Diseases on Rituximab: A Subanalysis of the COVID-19 Vaccine Booster in Immunocompromised Rheumatic Diseases (COVBIRD) Study
Laurianne Simard¹, Nathalie Amiable², Ines Colmegna³, Anne-Sophie Julien⁴, Sonia Léger-Thériault⁵, Alexandra Godbout⁴, Lison Fournier⁶, Giuliana Alfonso⁵, Josiane Bourre-Tessier⁷, Marie Hudson⁸, Nicolas Richard⁹, Jean-Paul Makhzoum¹⁰, Arielle Mendel¹¹, Sasha Bernatsky¹², Marc Dionne⁶, Michael Libman⁵, Gaston De Serres⁶ and Paul Fortin¹³, ¹Universite Laval, Quebec, QC, Canada, ²Centre de recherche du CHU de Québec – Université Laval, Quebec City, QC, Canada, ³The Research Institute of the McGill University Health Centre, Montréal, QC, Canada, ⁴Centre de recherche du CHU de Québec – Université Laval, Quebec, QC, Canada, ⁵MUHC, Montreal, Canada, ⁶Centre de recherche du CHU de Québec – Université Laval, Quebec, Canada, ⁷Centre hospitalier de l'Universite de Montreal, Montreal, QC, Canada, ⁸McGill University, Montréal, QC, Canada, ⁹Hopital Maisonneuve Rosemont, Montreal, QC, Canada, ¹⁰Universite de Montreal, Montreal, Canada, ¹¹McGill University Health Centre, Montréal, QC, Canada, ¹²Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ¹³Centre ARThrite - CHU de Québec - Université Laval, Quebec, QC, Canada
Background/Purpose: Patients with systemic autoimmune rheumatic diseases (SARD) treated with B-cell-depleting therapies such as rituximab (RTX) have impaired humoral immune responses, increasing their susceptibility to…
Abstract Number: 0664 • ACR Convergence 2025
Pharmacodynamic Effects of Obinutuzumab on B cells and Serological Markers in Patients With Active Lupus Nephritis: Results From a Phase III Trial
Richard Furie¹, Ioannis Parodis², Rachel Jones³, Liz Lightstone⁴, Olivia Hwang⁵, Amelia Au-Yeung⁵, Imran Hassan⁶, Huiyan Mao⁶, William Pendergraft⁵, Jay Garg⁵, Harini Raghu⁵ and Brad Rovin⁷, ¹Division of Rheumatology, Northwell Health, Great Neck, NY, ²Karolinska Institutet and Karolinska University Hospital, Department of Medicine Solna, Division of Rheumatology, Stockholm, Sweden, ³Renal Medicine, Cambridge University Hospitals, Cambridge, England, United Kingdom, ⁴Department of Immunology and Inflammation, Faculty of Medicine, Imperial College London, London, England, United Kingdom, ⁵Genentech, Inc., South San Francisco, CA, ⁶Hoffmann-La Roche Ltd, Mississauga, ON, Canada, ⁷The Ohio State University, Columbus, OH
Background/Purpose: Lupus nephritis (LN) is a severe manifestation of systemic lupus erythematosus, marked by kidney inflammation and damage. Obinutuzumab, a glycoengineered, type II CD20 antibody…
Abstract Number: 0014 • ACR Convergence 2025
NKX019, an allogeneic off-the-shelf CD19 targeting CAR-NK cell therapy, induces deep CD19+ B cell depletion in hematological malignancy and models of autoimmune disease
Mira Tohmé, Meriam Vejiga, Wendy Yu, Emily Kang, Katharine Yu, Jessica Sood, Ivan Chan, Kyle Hansen, David Shook and Phung Gip, Nkarta, South San Francisco, CA
Background/Purpose: Autologous CAR T-cell therapies have remarkable clinical activity in autoimmune disease (AD) via B-cell targeting, with many patients achieving durable, drug-free remission. However, safety…
Abstract Number: 2476 • ACR Convergence 2025
Blinatumomab in rapid progressive systemic sclerosis
Christina Gebhardt¹, Franziska Szelinski², Hector Rincon-Arevalo², Giulia Magno³, Veit Buecklein³, Gerulf Haenel⁴, Gerhard Zugmaier⁵, Michael von Bergwelt³, Marion Subklewe³, Thomas Dörner⁶, Alla Skapenko⁷ and Hendrik Schulze-Koops⁷, ¹LMU Hospital, Division for Rheumatology and Clinical Immunology, München, Germany, ²Charite Universitétsmedizin Berlin, Germany, Berlin, Germany, ³LMU Klinikum, Med. Klinik und Poliklinik III, Munich, Germany, ⁴LMU Gene Center, Munich, Germany, ⁵Amgen, Munich, Germany, ⁶Charite Universitétsmedizin Berlin, Germany and DRFZ, Berlin, Berlin, Germany, ⁷LMU Hospital, Division for Rheumatology and Clinical Immunology, Munich, Bayern, Germany
Background/Purpose: Systemic sclerosis is a severe, potentially fatal disease, characterized by progressive fibrosis of skin and internal organs. Blinatumomab is a bispecific CD3/CD19-T-cell engager (BiTe)…
Abstract Number: 1697 • ACR Convergence 2025
Dynamic Effects of T cell Engager Therapy on B and T cells in Autoimmune Disease.
Laura Bucci¹, Tobias Rothe², Ann-Kathrin Goetz³, Kirill Anoshkin¹, Danae-Mona Nöthling¹, Melanie Hagen¹, Sebastian Böltz¹, Andreas Wirsching¹, Georg Schett⁴ and Ricardo Grieshaber-Bouyer⁵, ¹Department of Medicine ³ - Rheumatology and Immunology, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg and Uniklinikum Erlangen, Erlangen, Germany, ²Department of Medicine ³ - Rheumatology and Immunology, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg and Uniklinikum Erlangen, Erlagen, Germany, ³Department of Medicine ³ - Rheumatology and Immunology, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg and Uniklinikum Erlangen, Erlangen, ⁴Uniklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Germany, Erlangen, Germany, ⁵University Hospital Erlangen, Erlangen, Germany
Background/Purpose: Treatment of autoimmune disease with T cell engagers (TCEs) leads to profound peripheral B cell depletion, followed by their reconstitution. However, the dynamics of…
Abstract Number: 1093 • ACR Convergence 2025
Rituximab Associated Risk for Progressive Multifocal Leukoencephalopathy Among Patients with Systemic Lupus Erythematosus: A Retrospective Cohort Study
Blake Baay¹, Lorien Nassi² and Zachary Most³, ¹Scottish Rite for Children, Dallas, TX, ²UT Southwestern, Children's Medical Center, and Scottish Rite for Children, Dallas, TX, ³UT Southwestern, Dallas, TX
Background/Purpose: Rituximab is one of the many immunosuppressive medications used to treat SLE that can increase a patient’s risk for developing progressive multifocal leukoencephalopathy (PML),…
Abstract Number: 0656 • ACR Convergence 2025
Low-dose belimumab reduced disease flares in patients with systemic lupus erythematosus at low disease activity: a multicenter, randomized, double-blind, placebo-controlled trial
Fangfang Sun¹, Huijing Wang¹, Danting Zhang¹, Nan Shen¹, Sheng Chen¹, Tiing Li¹, Weiguo Wan², Shengming Dai³ and Shuang Ye⁴, ¹Renji Hospital, Shanghai, China (People's Republic), ²Huashan Hospital, Shanghai, China (People's Republic), ³Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai, China (People's Republic), ⁴Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China, Shanghai, Shanghai, China (People's Republic)
Background/Purpose: B-lymphocyte stimulator was involved in the pathogenesis of SLE. The humanized monoclonal antibody belimumab with 10mg/kg was effective for active patients. The efficacy of…
Abstract Number: 0010 • ACR Convergence 2025
XmAb657, a CD19 x CD3 T-Cell Engaging Bispecific Antibody for Autoimmune Disease
Matthew Bernett¹, Gregory Moore², Katrina Bykova², Viralkumar Davra², Seung Chu², Michael Sheard², Ruschelle Love², Norman Barlow², Engie Salama², Jitendra Kanodia², Panida Lertkiatmongkol², Dipankar Chaudhuri², Kendra Avery², Hanh Nguyen², Rumana Rashid², Ke Liu², Jing Qi², Araz Eivazi², Thuy Truong², Sher Karki², James Ernst², Rena Bahjat² and John Desjarlais², ¹Xencor, Inc., Pasadena, CA, ²Xencor, Inc., Pasadena
Background/Purpose: B cell depletion is a validated therapeutic strategy in autoimmune disease, but current approaches targeting CD20 may only partially eliminate disease-driving subsets such as…
Abstract Number: L17 • ACR Convergence 2024
Allogenic CD19 CAR NK Cells Therapy in Refractory Systemic Lupus Erythematosus: An Open-label, Single Arm, Prospective and Interventional Clinical Trial
Yiyi Yu¹, Ruina Kong¹, Xia Xu¹, Suxuan Liu¹, Qian Chen¹, Xiaofang Li², Ming Sun², Jianmin Yang¹, Dongbao Zhao¹ and Jie Gao¹, ¹Changhai Hospital, Shanghai, China, ²Rui Therapeutics, Nanjing, China
Background/Purpose: Treatment of systemic lupus erythematosus (SLE) typically necessitates long-term immunosuppression with hormones, immunosuppressants and biologics. CD19-targeting chimeric antigen receptor (CAR) T cells have shown excellent…
Abstract Number: 0006 • ACR Convergence 2024
NX-5948, a Clinical-Stage BTK Degrader, Achieves Deep Suppression of BCR, TLR, and FcR Signaling in Immune Cells and Demonstrates Efficacy in Preclinical Models of Arthritis and Other Inflammatory Diseases
Mark Noviski¹, Jun Ma¹, Nivetha Brathaban¹, Aishwarya Kumar¹, Dhwani Haria¹, Jenny McKinnell¹, Robert Cass¹, Frederick Cohen¹, Davorka Messmer², Gwenn Hansen¹ and Ryan Rountree¹, ¹Nurix Therapeutics, San Francisco, CA, ²Nurix Therapeutics, San Diego, CA
Background/Purpose: Bruton’s tyrosine kinase (BTK) mediates signaling downstream of the B cell receptor (BCR), toll-like receptors (TLRs), and Fc receptors (FcRs). This makes BTK an…
Abstract Number: 0536 • ACR Convergence 2024
A Population Modeling and Simulation of the Effect of Obexelimab Exposure on the QTc Interval in Healthy Volunteers and Patients with Rheumatoid Arthritis or IgG4-Related Disease
Claire Mukashyaka¹, Xiaodong Wang¹, Sujata Arora¹, Mason Yamashita¹, Allen Poma¹ and Tanya Fischer², ¹Zenas BioPharma, Waltham, MA, ²Zenas BioPharma, Waltham, CA
Background/Purpose: Obexelimab is a novel bifunctional antibody that inhibits B cells, CD19-expressing plasma cells, and plasmablast activity and has the potential to provide clinical benefit…
Abstract Number: 1551 • ACR Convergence 2024
Efficacy of Belimumab on Different Phenotypes of Joint and Skin Manifestations of Systemic Lupus Erythematosus: Preliminary Data from a Multicenter, Nationwide, Cohort of Patients: The BElimumab in Real Life Setting Study-New Joint and Skin (BeRLISS-NeJS)
Luca Iaccarino¹, Marisol Bracalenti², Alberto Cauli³, Lorenzo Cavagna⁴, Rossella De Angelis⁵, Roberto Depascale², Giacomo Emmi⁶, Roberto Gerli⁷, Marcello Govoni⁸, Alberto Lo Gullo⁹, Simone Negrini¹⁰, Luca Quartuccio¹¹, Maurizio Rossini¹², Carlo Salvarani¹³, Paola Tomietto¹⁴, Angelo Vacca¹⁵, Margherita Zen¹⁶ and doria Andrea², ¹University of Padua, PADOVA, Italy, ²University of Padova, Padova, Italy, ³University of Cagliari, Cagliari, Italy, ⁴University of Pavia and Fondazione IRCCS Policlinico San Matteo Hospital of Pavia, Pavia, Pavia, Italy, ⁵Università Politecnica delle Marche, Ancona, Italy, ⁶University of Trieste, Trieste, Italy, ⁷University of Perugia, Perugia, Italy, ⁸Rheumatology Unit, Department of Medical Sciences, University of Ferrara and Azienda Ospedaliero-Universitaria S.Anna, Ferrara, Italy, Ferrara, Italy, ⁹Rheumatology Unit, Papardo Hospital, Messina, Italy, ¹⁰University of Genova, Genova, Italy, ¹¹Division of Rheumatology, Department of Medicine (DMED), University of Udine, Udine, Italy, Udine, Italy, ¹²Rheumatology Unit, University of Verona, Verona, Italy, ¹³Azienda USL-IRCCS di Reggio Emilia and University of Modena and Reggio Emilia, Reggio Emilia, Italy, Reggio Emilia, Italy, ¹⁴Azienda Sanitaria Universitaria Giuliano Isontina, trieste, Italy, ¹⁵University of Bari, Bari, Italy, ¹⁶University of Padova, Padova, Padua, Italy
Background/Purpose: To evaluate the efficacy of belimumab on different skin and joint manifestations of the disease in a multicenter, nationwide, cohort (BeRLISS-NeJS) of patients with…

« Previous Page
1
…
4
5
6
7
8
…
17
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].